MAVS/CMTM6 axis couples mitochondrial homeostasis to immunogenic senescence via CCL3-driven T-cell recruitment in renal carcinoma
Our findings establish the tumor-intrinsic MAVS/CMTM6/CCL3 axis as a previously unrecognized critical regulator of senescence-driven antitumor immunity in renal carcinoma. Therapeutic targeting of this axis presents a promising strategy to curtail tumor progression and potentiate immunotherapy.
Authors
- Shidong Zuo
- Senming Cao
- Jichen Wang (ORCID: https://orcid.org/0000-0001-5370-056X)
- Jiali Ye (ORCID: https://orcid.org/0000-0002-3235-5979)
- X G Chen
- Qi Huang (ORCID: https://orcid.org/0000-0001-6322-9492)
- Chi Zhang (ORCID: https://orcid.org/0009-0000-4820-5126)
- Xu Zhang (ORCID: https://orcid.org/0000-0002-2395-7986)
- Hanfeng Wang (ORCID: https://orcid.org/0000-0003-1456-9882)
- Qiyang Liang
- Minghui Yang
- Yu Gao
- Donglai Shen
- Wen Tao
- Xin Ma
- Yan Huang
- Yang Fan
Institutions
- Nankai University (CN)
- Chinese PLA General Hospital (CN)
- Beijing Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-011477
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00